Related Experiment Video
Updated: Aug 19, 2026

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists
Published on: November 15, 2013
Modulation of human nuclear receptor LRH-1 activity by phospholipids and SHP
Eric A Ortlund1, Yoonkwang Lee, Isaac H Solomon
1Department of Chemistry, Lineberger Comprehensive Cancer Center, School of Medicine, University of North Carolina at Chapel Hill, 27599, USA.
Abstract:
The human nuclear receptor liver receptor homolog 1 (hLRH-1) plays an important role in the development of breast carcinomas. This orphan receptor is efficiently downregulated by the unusual co-repressor SHP and has been thought to be ligand-independent. We present the crystal structure at a resolution of 1.9 A of the ligand-binding domain of hLRH-1 in complex with the NR box 1 motif of human SHP, which we find contacts the AF-2 region of hLRH-1 using selective structural motifs. Electron density indicates phospholipid bound within the ligand-binding pocket, which we confirm using mass spectrometry of solvent-extracted samples. We further show that pocket mutations reduce phospholipid binding and receptor activity in vivo. Our results indicate that hLRH-1's control of gene expression is mediated by phospholipid binding, and establish hLRH-1 as a novel target for compounds designed to slow breast cancer development.
Insights
The liver receptor homolog 1 (hLRH-1) binds phospholipids, revealing its mechanism in gene regulation. This finding identifies hLRH-1 as a new target for breast cancer therapies.
Area of Science:
- Molecular biology
- Structural biology
- Biochemistry
Background:
- The human nuclear receptor liver receptor homolog 1 (hLRH-1) is implicated in breast carcinoma development.
- hLRH-1 is downregulated by the co-repressor SHP and was considered ligand-independent.
Purpose of the Study:
- To elucidate the structural basis of hLRH-1 regulation by SHP.
- To investigate the role of potential ligands in hLRH-1 activity.
Main Methods:
- X-ray crystallography to determine the structure of hLRH-1 bound to SHP.
- Mass spectrometry to identify bound ligands.
- In vivo studies with mutated hLRH-1.
Main Results:
- The crystal structure revealed SHP's interaction with the AF-2 region of hLRH-1.
- Electron density indicated phospholipid binding within the hLRH-1 ligand-binding pocket.
- Mutations in the pocket impaired phospholipid binding and receptor activity.
Conclusions:
- hLRH-1's gene expression control is mediated by phospholipid binding.
- hLRH-1 represents a novel therapeutic target for slowing breast cancer progression.
Related Concept Videos
Transducer Mechanism: Nuclear Receptors
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Regulation of Nuclear Protein Sorting
Internal Receptors
Phosphoinositides and PIPs
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
Co-activators and Co-repressors
Amplifying Signals via Second Messengers

